Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.

ABSTRACT:

Background

Gastric cancer (GC) is a heterogeneous disease, and is a leading cause of cancer deaths in Eastern Asia. Genomic analysis, such as whole-exome sequencing (WES), can help identify key genetic alterations leading to the malignancy and diversity of GC, and may help identify new drug targets.

Methods

We identified genomic alterations in a cohort of 38 GC patients, including 26 metastatic and 12 non-metastatic patients. We analyzed the association between novel gene mutations and copy number variations (CNVs) with tumor metastasis and patient survival.

Results

A number of significantly mutated genes in somatic and germline cells were identified. Among them, ATAD3B somatic mutation, a potential biomarker of immunotherapy in stomach cancers, was associated

SUBMITTER: Zhu Z 

PROVIDER: S-EPMC7729362 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature